The company intends to use the funds to build out its team and platform capabilities in line with the its mission to enable next-generation solutions for emerging RNA therapeutics.Founded by George Church, PhD, Daniel Wiegand, Jonathan Rittichier, PhD, and Dan Ahlstedt as a technology spinout from the Wyss Institute for Biologically Inspired Engineering at Harvard University, EnPlusOne is a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides. It leverages an ezRNA synthesis platform that can incorporate a diverse array of nucleotide modifications to support direct RNA synthesis, and a vast array of RNA solution applications. The RNA synthesis platform aims to target synthesis lengths greater than 100-nt, large-scale GMP manufacturing, and novel therapeutic modifications in collaboration with industry partners.30/09/2022
